| Filed On | Filing |
|---|---|
| 15 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated as of June ... |
| 06 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 29 Jun 2026 |
Form 4: Preston Heather, Director
Granted 5,860 Stock Option (Right to Buy) |
| 29 Jun 2026 |
Form 4: Chavez Margarita, Director
Granted 5,860 Stock Option (Right to Buy) |
| 29 Jun 2026 |
Form 4: Martell Bridget A, Director
Granted 5,860 Stock Option (Right to Buy) |
| 29 Jun 2026 |
Form 4: Scopa James Paul, Director
Granted 5,860 Stock Option (Right to Buy) |
| 29 Jun 2026 |
Form 4: Nuechterlein Carole, Director
Granted 5,860 Stock Option (Right to Buy) |
| 29 Jun 2026 |
Form 4: Hirth Peter, Director
Granted 5,860 Stock Option (Right to Buy) |
| 26 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 24 Jun 2026 | SCHEDULE 13D |
| 15 May 2026 | SCHEDULE 13G |
| 15 May 2026 | SCHEDULE 13G/A |
| 07 May 2026 | 10-Q |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition |
| 29 Apr 2026 | DEFA14A |
| 29 Apr 2026 | ARS |
| 29 Apr 2026 |
Proxy statement: annual meeting on June 25, 2026
say-on-pay vote |
| 21 Apr 2026 | 8-K: Entry into a Material Definitive Agreement |
Loading...
